Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL420232 | 1.00 | BTK (0.58) | BTKGAAEPHX1CCR1KDM1A | |
| SCHEMBL1444279 | 1.00 | BTK (0.58) | BTKGAAEPHX1CCR1KDM1A | |
| SCHEMBL1756657 | 1.00 | BTK (0.58) | BTKGAAEPHX1CCR1KDM1A | |
| SCHEMBL14346489 | 1.00 | BTK (0.58) | BTKGAAEPHX1CCR1KDM1A | |
| SCHEMBL169972 | 1.00 | BTK (0.58) | BTKGAAEPHX1CCR1KDM1A | |
| SCHEMBL2560495 | 1.00 | BTK (0.58) | BTKGAAEPHX1CCR1KDM1A | |
| SCHEMBL2563637 | 1.00 | BTK (0.58) | BTKGAAEPHX1CCR1KDM1A | |
| SCHEMBL29046628 | 0.98 | BTK (0.56) | BTKGAAEPHX1CCR1KDM1A | |
| SCHEMBL29046627 | 0.98 | BTK (0.56) | BTKGAAEPHX1CCR1KDM1A | |
| SCHEMBL19217725 | 0.98 | BTK (0.56) | BTKGAAEPHX1CCR1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3533797-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-12-20 | — | — | EP | disclosed |
| US-11807618-B2 | Thiophene derivatives as antiviral agents | ENYO PHARMA (FR) | 2023-11-07 | — | — | US | disclosed |
| CN-116547270-A | 4- (2-fluoro-4-methoxy-5-3- (((1-methylcyclobutyl) methyl) carbamoyl) bicyclo [2.2.1] hept-2-yl) carbamoyl) phenoxy) -1-methylcyclohexane-1-carboxylic acid derivatives and similar compounds as RXFP1 modulators for the treatment of heart failure | 阿斯利康(瑞典)有限公司 | 2023-08-04 | — | — | CN | disclosed |
| US-20220213053-A1 | THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS | ENYO PHARMA (FR) | 2022-07-07 | — | — | US | disclosed |
| EP-3562818-B1 | THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS | ENYO PHARMA (FR) | 2022-05-18 | — | — | EP | disclosed |
| EP-3984991-A1 | METHOD FOR SYNTHESIZING ATORVASTATIN CALCIUM INTERMEDIATE BY USING MULTI-COMPONENT ONE-POT METHOD | Zhejiang Hongyuan Pharma Co., Ltd (CN) | 2022-04-20 | — | — | EP | disclosed |
| US-11279683-B2 | Thiophene derivatives as antiviral agents | ENYO PHARMA (FR) | 2022-03-22 | — | — | US | disclosed |
| CN-111032651-A | Heterocyclic compounds | 武田药品工业株式会社 | 2020-04-17 | — | — | CN | disclosed |
| EP-2694472-B1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-20190352275-A1 | THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS | ENYO PHARMA (FR) | 2019-11-21 | — | — | US | disclosed |
| CN-1802375-A | Beta-carbolines useful for treating inflammatory disease | MILLENNIUM PHARM INC (US) | 2006-07-12 | — | — | CN | disclosed |
| CN-1798729-A | Benzamide nitrile derivatives | HOFFMANN LA ROCHE (CH) | 2006-07-05 | — | — | CN | disclosed |
| EP-1294679-B1 | BETA-AMINO ACID NITRILE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2005-09-21 | — | — | EP | disclosed |
| US-20040204454-A1 | Lactam-containing cyclic diamines and derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | disclosed |
| US-20030229084-A1 | Barbituric acid derivatives as inhibitors of TNF-alpha converting enzyme (TACE) and/or matrix metalloproteinases | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-11 | — | — | US | disclosed |
| WO-2003053941-A2 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-ALPHA CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
| EP-1294679-A1 | BETA-AMINO ACID NITRILE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-03-26 | — | — | EP | disclosed |
| US-6462076-B2 | CYSTEINE PROTEASE INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES ASSOCIATED WITH CYSTEINE PROTEASES, SUCH AS OSTEOPOROSIS, OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, TUMOR METASTASIS, ANGINA PECTORIS, PLAQUE RUPTURE AND STROKE ETC. | HOFFMANN-LA ROCHE INC. | 2002-10-08 | — | — | US | disclosed |
| US-20020016361-A1 | Beta-amino acid nitrile derivatives as cathepsin K inhibitors | HOFFMANN-LA ROCHE INC. | 2002-02-07 | — | — | US | disclosed |
| WO-2001096285-A1 | BETA-AMINO ACID NITRILE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213053-A1 | THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS | MAVS, EIF2AK2, IRF3 | BTK 1475/4885GAA 355/4885EPHX1 3631/4885 |
| US-20040204454-A1 | Lactam-containing cyclic diamines and derivatives as factor Xa inhibitors | PEPD, TFPI, F2 | BTK 710/4885GAA 983/4885EPHX1 2522/4885 |
| US-20030229084-A1 | Barbituric acid derivatives as inhibitors of TNF-alpha converting enzyme (TACE) and/or matrix metalloproteinases | TNF, MMP3, TIMP3 | BTK 2786/4885GAA 93/4885EPHX1 1053/4885 |
| US-20020016361-A1 | Beta-amino acid nitrile derivatives as cathepsin K inhibitors | CTSK, CTSH, UACA | BTK 1065/4885GAA 150/4885EPHX1 2739/4885 |
| US-11279683-B2 | Thiophene derivatives as antiviral agents | MAVS, EIF2AK2, IRF3 | BTK 1364/4885GAA 238/4885EPHX1 3295/4885 |
| US-20190352275-A1 | THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS | MAVS, EIF2AK2, IRF3 | BTK 1364/4885GAA 238/4885EPHX1 3295/4885 |
| US-11807618-B2 | Thiophene derivatives as antiviral agents | MAVS, EIF2AK2, IRF3 | BTK 1475/4885GAA 355/4885EPHX1 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.